Some lung cancers are caused by a change, or mutation, in a gene called EGFR. Afatinib is an investigational drug shown to be active against cancers with this mutation. It is not, however, routinely used in combination with radiation therapy.
The use of chemotherapy and radiation therapy given together at the same time is an approach to treating lung cancers that cannot be surgically removed. In this study, researchers want to find the best dose of afatinib that can be given with chemotherapy and radiation therapy in patients with EGFR-mutant non-small cell lung cancers. The chemotherapy drugs used in this study will include cisplatin or carboplatin in addition to pemetrexed.